FM888: A New Target Analgesic for AC1

The first in the world and fill the gap in the international market: FM888 is the first global brain-based special drug for central neuralgia, and the first brand-new drug to exert analgesic effects by inhibiting synaptic plasticity, filling the market gap.

FM888 is a new target analgesic for AC1 (Adenylate Cyclase Subtype 1), which is used for the treatment of central neuralgia. It is in line with the current trend of analgesic drugs development and the market prospect is extremely broad. 

Pain, especially central neuralgia, has a high incidence and difficulties for diagnosis and treatment. In recent years, pain, especially chronic pain, has gradually been confirmed as a disease. The basic treatment is to remove the source of pain, varies the central perception, change the central pain transmission, and block the central pathway.

FM888 exerts analgesic effects by inhibiting central plasticity, which is theoretically innovative. The effect is neural activity-dependent, thus reducing central side effects, and may fill a gap in non-addictive analgesics, which has a great value.

As a new analgesic target for AC1, FM888 is designed to replace classical analgesics for central neuralgia, which is in line with the current trend of analgesics and has a very broad market prospect.